2025 France Autologous Cell Therapy Market Revenue Opportunities Report
Description
The 2025 France Autologous Cell Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market in France include Cellectis, Bluebird Bio, Coave Therapeutics, and Corteria Pharmaceuticals. Cellectis, based in France, is a leader in gene-edited allogeneic and autologous cell therapies, using TALEN technology to develop cancer immunotherapies. Bluebird Bio has contributed significantly to hematopoietic stem cell gene therapies and is advancing autologous gene therapy products, including those for rare genetic disorders. Coave Therapeutics, headquartered in Paris, develops gene therapies targeting ocular and CNS diseases using innovative viral vector platforms and has attracted significant funding to advance its pipeline. Corteria Pharmaceuticals focuses on autologous therapies for heart failure subpopulations, developing novel CRF2 agonists with ongoing clinical trials and strong investment backing.
These companies benefit from France’s robust biotech ecosystem and government support, positioning the country as a leader in gene and cell therapies in Europe. France’s leading research institutes and clusters, such as Genethon and Institut Curie, foster innovation and facilitate translational development of autologous cell therapies. Treatments targeting cancer, rare genetic diseases, and cardiovascular conditions are at the forefront of clinical and commercial advancement by these firms, with forecasts projecting significant growth in cell and gene therapies launched in France through 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market in France include Cellectis, Bluebird Bio, Coave Therapeutics, and Corteria Pharmaceuticals. Cellectis, based in France, is a leader in gene-edited allogeneic and autologous cell therapies, using TALEN technology to develop cancer immunotherapies. Bluebird Bio has contributed significantly to hematopoietic stem cell gene therapies and is advancing autologous gene therapy products, including those for rare genetic disorders. Coave Therapeutics, headquartered in Paris, develops gene therapies targeting ocular and CNS diseases using innovative viral vector platforms and has attracted significant funding to advance its pipeline. Corteria Pharmaceuticals focuses on autologous therapies for heart failure subpopulations, developing novel CRF2 agonists with ongoing clinical trials and strong investment backing.
These companies benefit from France’s robust biotech ecosystem and government support, positioning the country as a leader in gene and cell therapies in Europe. France’s leading research institutes and clusters, such as Genethon and Institut Curie, foster innovation and facilitate translational development of autologous cell therapies. Treatments targeting cancer, rare genetic diseases, and cardiovascular conditions are at the forefront of clinical and commercial advancement by these firms, with forecasts projecting significant growth in cell and gene therapies launched in France through 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
